NewcelX (NCEL) Common Equity (2019 - 2025)
NewcelX (NCEL) posted quarterly Common Equity of $7.2 million for Q4 2025, up 190.67% year-over-year from $2.5 million in Q4 2024, and up 148.07% quarter-over-quarter from -$15.1 million in Q2 2025.
NewcelX (NCEL) Common Equity (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Common Equity for 7 consecutive years, with $7.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity rose 190.67% year-over-year to $7.2 million; the TTM figure through Dec 2025 stood at $7.2 million (up 190.67% YoY), while the FY2025 annual figure was $7.2 million, up 190.67% from the prior year.
- Common Equity improved to $7.2 million in Q4 2025 per NCEL's latest filing, from -$15.1 million in the prior quarter.
- Across five years, Common Equity topped out at $7.2 million in Q4 2025 and bottomed at -$15.1 million in Q2 2025.
- Historically, Common Equity has averaged -$1.8 million across 5 years, with a median of -$576000.0 in 2023.
- Annual changes were most pronounced in 2024 — Common Equity plunged 4915.56% — and 2025, when it soared 190.67%.
- NewcelX's Common Equity stood at $542388.0 in 2021, then sank by 79.53% to $111000.0 in 2022, then tumbled by 1178.38% to -$1.2 million in 2023, then plunged by 568.0% to -$8.0 million in 2024, then jumped by 190.67% to $7.2 million in 2025.
- Business Quant data shows NCEL's Common Equity at $7.2 million in Q4 2025, -$15.1 million in Q2 2025, and -$8.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 7.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.25 Mn |
| Jun 30, 2025 | -15.08 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Jun 30, 2024 | -2.17 Mn |
| Dec 31, 2023 | -1.20 Mn |
| Jun 30, 2023 | 45,000.00 |
| Dec 31, 2022 | 111,000.00 |
| Jun 30, 2022 | -4.04 Mn |
| Dec 31, 2021 | 542,388.00 |
| Jun 30, 2021 | 4.25 Mn |
| Dec 31, 2020 | -8.98 Mn |
| Dec 31, 2019 | -6.17 Mn |